Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MIF | P14174 | 1/20 | 0.42 |
| ▸ | APP | P05067 | 1/20 | 0.36 |
| ▸ | AGXT | P21549 | 3/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.35 |
| ▸ | MGLL | Q99685 | 1/20 | 0.34 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.34 |
| ▸ | NR1H3 | Q13133 | 4/20 | 0.34 |
| ▸ | DHODH | Q02127 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.33 |
| ▸ | GRM5 | P41594 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6735952 | 0.71 | NPC1 (0.40) | ALOX5 | |
| SCHEMBL30797233 | 0.69 | MIF (0.41) | MIFAPPAGXTBRD4CREBBP | |
| SCHEMBL19251341 | 0.68 | AGXT (0.71) | AGXTL3MBTL1 | |
| SCHEMBL13451177 | 0.68 | ADRB1 (0.62) | AGXT | |
| SCHEMBL791963 | 0.68 | ALDH1A1 (0.54) | BRD4L3MBTL1 | |
| SCHEMBL487468 | 0.67 | IDO1 (0.48) | AGXT | |
| SCHEMBL13075582 | 0.66 | MIF (0.43) | MIFAPP | |
| SCHEMBL18933602 | 0.65 | AGXT (0.46) | MIFAGXT | |
| SCHEMBL14288609 | 0.65 | AGXT (0.73) | AGXT | |
| SCHEMBL10059368 | 0.65 | KDM4E (0.55) | MIFAPPMGLLDHODH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020031536-A1 | Cosmetic compositions based on 4,5-pyrazolinediones, novel 4,5-pyrazolinediones, process for their preparation and uses thereof | L'OREAL SA | 2002-03-14 | — | — | US | disclosed |
| US-6322775-B1 | FOR COLORING THE SKIN AND/OR THE HAIR; SIDE EFFECTS REDUCTION; STABILITY | L'OREAL S.A. (FR) | 2001-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020031536-A1 | Cosmetic compositions based on 4,5-pyrazolinediones, novel 4,5-pyrazolinediones, process for their preparation and uses thereof | PPARD, PLIN5, PDK4 | MIF 4679/4885APP 2077/4885AGXT 2620/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.